ArticlePDF Available

Monoclonal Antibodies for Cancer Immunotherapy

March 2007

Authors:

Parul University

Ganpat University

Over the period of last decade, many new and non-conventional (i.e. different from chemotherapy) approaches for cancer therapeutics have been emerged as alternative anti-cancer treatment and would have been successful also. However, there are few limitations with these newer approaches like presence of soluble form of antigen in serum, which effectively interfered with the interaction antibody with tumor cell, modulation and loss of the antibody-antigen complexes from the tumor cell surface before antibody mediated killing occur and outgrowth of tumor cells not expressing the antigen. Monoclonal antibodies make an important contribution to the therapeutic treatment of non-Hodgkin lymphoma, acute myeloid leukemia, breast cancer, and now colorectal cancer and prostate cancer.

Content uploaded by Jignesh Patel

Content may be subject to copyright.

ResearchGate has not been able to resolve any citations for this publication.

ResearchGate has not been able to resolve any references for this publication.

Article

Full-text available

Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Con...

July 2012 · Antibodies

Immunotherapy has emerged as an alternative strategy to treat malignancies in addition to conventional radio- and chemotherapy. There has been a plethora of evidence that the immune system is able to control tumor outgrowth and a number of strategies have been put forward to utilize this ability for immunotherapy. However, some of these strategies have not been very efficient and their success ... [Show full abstract] has been limited by tumor evasion mechanisms. A promising approach to engage effector cells of the immune system overcoming some of the escape mechanisms has been introduced more than two decades ago. This approach is based on bispecific antibodies. Here we summarize the evolution of bispecific antibodies, their improvement, remaining obstacles and some controversial reports.

Article

Serum S100B Levels Correlate with Clinical Benefit in a Metastatic Melanoma Patient Treated by CTLA-...

October 2013 · Onkologie

Background: Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells. In patients with metastatic melanoma, anti-CTLA-4 antibody therapy with ipilimumab achieves durable cancer regression in approximately 10-15% of patients. In the face of complex and sometimes delayed tumor response patterns, prognostic and predictive biomarkers are ... [Show full abstract] needed to monitor therapy outcomes and to identify early potential long-term survivors who might also benefit from therapy re-induction. Case report: The clinical case of a 49-year-old male patient with metastatic melanoma and unfavorable prognostic factors is presented. The time course of the serum biomarker S100B during initial anti-CTLA-4 therapy correlated very well with the clinical situation and, in the present case, proved its potential value as an early biomarker of a subsequently observed radiological response in this stage IV melanoma patient. The observed clinical response lasted for more than 24 months. Conclusions: Further efforts are required to better understand the patterns of response and the immunological tumor response in patients undergoing CTLA-4 blockade. A validation of S100B as a marker to identify early long-term responders among patients treated with ipilimumab is warranted.

Article

Full-text available

Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor...

February 2020 · Science Advances

The response to programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) blockade in cancer immunotherapy is limited because of multiple immune evasion mechanisms. Here, a previously unknown strategy is proposed to synergize the nuclear factor κB (NF-κB) inhibition and PD-1 blockade for antitumor immunotherapy. A dual pH-sensitive nanocarrier loading curcumin (CUR) and anti–PD-1 ... [Show full abstract] monoclonal antibody (aPD-1) may bind to circulating PD-1 ⁺ T cells and then follow their infiltration into the tumor. Furthermore, the nanodrug bound to PD-1 ⁺ T cells may be released in the tumor microenvironment, leaving aPD-1 to block PD-1 on T cells and generating a CUR-encapsulated cationic nanodrug that can be easily taken up by tumor cells/tumor associated macrophages (TAMs). Thus, not only the antitumor T cells mediate efficient CUR delivery to tumor but also the efficient CUR delivery promotes the tumor infiltration of antitumor T cells, thereby resulting in effective activation of antitumor immunity.

Article

The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer

October 2014

Introduction: Immunotherapy is emerging as a powerful approach in cancer treatment. Preclinical data predicted the antineoplastic effects seen in clinical trials of programmed death-1 (PD-1) pathway inhibitors, as well as their observed toxicities. The results of early clinical trials are extraordinarily promising in several cancer types and have shaped the direction of ongoing and future ... [Show full abstract] studies. Areas covered: This review describes the biological rationale for targeting the PD-1 pathway with monoclonal antibodies for the treatment of cancer as a context for examining the results of early clinical trials. It also surveys the landscape of ongoing clinical trials and discusses their anticipated strengths and limitations. Expert opinion: PD-1 pathway inhibition represents a new frontier in cancer immunotherapy, which shows clear evidence of activity in various tumor types including NSCLC and melanoma. Ongoing and upcoming trials will examine optimal combinations of these agents, which should further define their role across tumor types. Current limitations include the absence of a reliable companion diagnostic to predict likely responders, as well as lack of data in early-stage cancer when treatment has the potential to increase cure rates.